The Coronavirus disease 2019 (COVID-19) outbreak has imposed the adoption of strategies to limit the risk of contagion for cancer patients without compromising their healthcare. As well as cancers of other sites, the treatment of certain ocular and periocular malignancies is considered non-deferrable and should proceed despite the pandemic. Delays in treatment of these patients may result in negative outcomes. Herein, we provide some practical considerations deriving from our experience at the Ocular Oncology Unit of Careggi University Hospital (Florence, Italy).
SudAJonesMBroggioJ, et al. Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann Oncol2020; 31: 1065–1074.
2.
SkaletAHAllenRCShieldsCL, et al. Considerations for the management and triage of ocular oncology cases during the COVID-19 pandemic. Ocul Oncol Pathol2020; 6(3): 1–4.
3.
OnkenMDWorleyLAEhlersJP, et al. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res2004; 64: 7205–7209.
4.
WorleyLAOnkenMDPersonE, et al. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res2007; 13(5): 1466–1471.
5.
OnkenMDWorleyLATuscanMD, et al. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn2010; 12: 461–468.
6.
DamatoBEleuteriATaktakAF, et al. Estimating prognosis for survival after treatment of choroidal melanoma. Prog Retin Eye Res2011; 30: 285–295.
7.
EleuteriADamatoBCouplandSE, et al. Enhancing survival prognostication in patients with choroidal melanoma by integrating pathologic, clinical and genetic predictors of metastasis. Int J Biomed Eng Technol2012; 8: 18–35.
8.
ShieldsCLKalikiSFurutaM, et al. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina2012; 32: 1363–1372.
9.
OnkenMDWorleyLACharDH, et al. Collaborative ocular oncology group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology2012; 119(8): 1596–1603.
10.
DeParisSWTaktakAEleuteriA, et al. External validation of the Liverpool uveal melanoma prognosticator online. Invest Ophthalmol Vis Sci2016; 57(14): 6116–6122.
11.
WalterSDChaoDLFeuerW, et al. Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma. JAMA Ophthalmol2016; 134: 734–740.
12.
ShieldsCLSayEATHasanreisogluM, et al. Cytogenetic abnormalities in uveal melanoma based on tumor features and size in 1059 patients: the 2016 W. Richard Green lecture. Ophthalmology2017; 124(5): 609–618.
13.
Vaquero-GarciaJLalondeEEwensKG, et al. PRiMeUM: a model for predicting risk of metastasis in uveal melanoma. Invest Ophthalmol Vis Sci2017; 58(10): 4096–4105.
14.
LuCWLiuXFJiaZF.2019-nCoV transmission through the ocular surface must not be ignored. Lancet2020; 395(10224): e39.
15.
AielloFGallo AfflittoGMancinoR, et al. Coronavirus disease 2019 (SARS-CoV-2) and colonization of ocular tissues and secretions: a systematic review. Eye (Lond)2020; 34(7): 1206–1211.
16.
SunCBWangYYLiuGH, et al. Role of the eye in transmitting human coronavirus: what we know and what we do not know. Front Public Health2020; 8: 155.
17.
BacheriniDBiaginiILenzettiC, et al. The COVID-19 pandemic from an ophthalmologist’s perspective. Trends Mol Med2020; 26(6): 529–531.
18.
RomagnaniPGnoneGGuzziF, et al. The COVID-19 infection: lessons from the Italian experience. J Public Health Policy2020; 41(3): 238–244.
